Furthermore, Ki-67 is a cell proliferation marker, and SU212-treated tumours had less Ki-67 expression compared to vehicle-treated tumours, indicating that treatment with SU212 inhibits tumour cell proliferation. Here, MKI67 is linked to neoplasm.